Stock Ticker

  • Loading stock data...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Closes A Licensing Deal With Merck & Co., Inc (NYSE:MRK)

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has today moved forward to make an announcement regarding its signing up into some definitive agreement where it was expected to grant Merck & Co., Inc (NYSE:MRK), which is commonly referred to as MSD Animal Health beyond borders of the United States and Canada as well with the full rights to […]

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Signs a Licensing Deal with Merck & Co., Inc. (NYSE:MRK) Animal Health

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) completes a Definitive Agreement giving Merck & Co., Inc. (NYSE:MRK) Animal Health the rights to build up and distribute Aurinia’s patented nano-micellar cyclosporin ophthalmic solution (VOS) for treating dry eye disorders in dogs. In this agreement, the Aurinia will obtain an upfront payment and they could receive more recompense which will […]

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Makes The Announcement Regarding Development Strategies For Voclosporin In Japan And Europe

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) after an elongated period of silence has come forward make the announcement regarding the outcome of discussions with both the Pharmaceutical and Medical Devices Agency (PMDA) and the European Medicines Agency (EMA). According to some reliable sources, the meeting was held in Japan and it was a great move that helped […]

Why Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Is In Focus?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced positive results from its 48-week Phase 2B study. The results not only achieved the complete and partial remission objectives, they were even superior over the 24-week results. Phase 3 study commence soon and has a high probability of success. The buzz Aurinia is a Canadian, clinical-stage, biotech firm based in […]

Sign Up To Get Our Latest Stocks Alerts